News
Venture firm Questa Capital closes US$397m fund to invest in health technology
The US venture growth equity firm aims to use the fund to modernise healthcare and address “critical” challenges
The US venture growth equity firm Questa Capital Management has closed a US$397m fund, bringing the firm’s aggregate committed capital to more than US$1bn.
The firm has an investment team of ten led by founder Ryan Drant and managing partners Brad Sloan and Shawn Conway, and currently manages 18 portfolio companies across its three healthcare sectors.
Its latest fund secured commitments from an investor base comprised of leading endowments, family offices, foundations, consultants, pension plans and fund-of-funds.
The fund is hoped to invest selectively in a portfolio of growth companies in healthcare services, health technology, and medical devices.
Drant, Questa founder and managing partner, said: “We are extremely pleased to close on Fund III despite a challenging fundraising environment.
“We are both grateful for the strong interest and ongoing support from our existing investors, and pleased to be starting long-term relationships with a small group of exceptional new limited partners.
“We are honored to work closely with our portfolio companies, including marquee companies like Dispatch Health, Cortica, Medrio, and Calyxo.
He added: “We are also energised by the opportunity set we see in the market, and look forward to continuing to build differentiated and high-growth healthcare companies in close collaboration with strong management teams.
“Questa will continue to partner with companies that share our vision and passion to improve clinical outcomes, efficiency, safety, and the patient experience to help address critical challenges in our healthcare system.”
Neil Hattangadi, CEO and co-founder of Cortica, a hybrid care provider developing care programmes for individuals with autism, said: “As Cortica continues to grow rapidly, Questa Capital has been an exceptional partner for our company as we build our team, broaden our relationships, and execute on our geographic expansion.
“Ryan and Brad are both extremely valued leaders on the Cortica board of directors. We congratulate them on their success in raising Fund III and look forward to our continued close collaboration.”
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Pregnancy
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Insight4 weeks agoDesigner perfumes recalled over banned chemical posing fertility risk
-
Fertility2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Wellness3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Menopause3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur5 days agoUS startup builds wearable hormone tracker
-
Menopause2 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
News4 weeks agoVerdane invest in Clue to accelerate the future of women’s health






